The US pharmaceutical company Pfizer and the German biotech company (BioNTech) are developing a new crown vaccine against the new coronavirus (SARS-CoV-2) variant virus strain Omicron (Omicron).
They announced on January 25 that clinical trials have been launched to test the efficacy of the new vaccine.
Pfizer and BioNTech said as many as 1,420 healthy individuals between the ages of 18 and 55 would participate in the clinical trial.
New crown vaccine: The picture shows a medical staff in Karachi, Pakistan, vaccinates students against the new crown on January 24.
(AP)
Participants will be divided into 3 groups: those in the first group who have received two doses of the original Pfizer vaccine 90 to 180 days before enrolling in the trial will receive one or two doses of the Omicron vaccine during the trial; Having received 3 doses of the original Pfizer vaccine during the first 90 to 180 days, they will receive one dose of the original Pfizer vaccine, or one dose of the vaccine against Omicron during the trial; those in the third group who did not receive the vaccine before participating in the trial will receive Three doses of the vaccine against Omicron were administered during the trial.
Study: "Ditch Needle" Booster Booster Antibody Volume Can Greatly Increase COVID-19 After Inoculation with Kexing Vaccine | Pfizer CEO: One dose per year is more ideal than frequent booster vaccinations Omicron ︱ US CDC study report: Need for booster vaccine
Kathrin Jansen, head of vaccine development at Pfizer, said: "While current research and real-world data show that vaccine boosters continue to provide high levels of protection against Omicron infection in vaccinated individuals who become seriously ill or require hospitalization, we recognize the need for a vaccine booster. Be prepared in case this protection diminishes over time, and be prepared to assist the population in dealing with Omicron and new mutant strains in the future."
